echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > FDA approves Banner's BAFIERTAM for the treatment of multiple sclerosis

    FDA approves Banner's BAFIERTAM for the treatment of multiple sclerosis

    • Last Update: 2020-05-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Banner Life Sciences LLC today announced that the U.SFood and Drug Administration (FDA) has approved its BAFIERTAM (polymethylamine) release capsule for the treatment of recurrent multiple sclerosis (MS)FACNS FAASM physician Daniel Wynn said: 'As a practicing neurologist treating MS patients, I am encouraged that the lower dose of BAFIERTAM (funtric sulpherate) is comparable to tecfidera and may improve the patient's gastrointestinal tolerance'
    BAFIERTAM is a prescription drug used to treat recurrent multiple sclerosis (MS) in adults, including clinically isolated syndrome, recurrent type, and active secondary developmentrecurrent-remission multiple sclerosis (RRMS) is the most common form of MS, accounting for 85% of MS patients, an estimated 2 million people worldwide, and is a debilitating autoimmune diseaseTreatment options for RRMS focus on symptom management, slowing disease progression and reducing recurrence
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.